Clinical Trials Logo

Vaccine clinical trials

View clinical trials related to Vaccine.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT06136832 Not yet recruiting - Vaccine Clinical Trials

Pneumonia Vaccine Education Intervention Study

PVI
Start date: April 30, 2024
Phase: N/A
Study type: Interventional

The goal of this interventional clinical trial is to investigate the impact of medicine and pharmacy-led education on patient acceptance rates of Prevnar 20 pneumonia vaccination in patients eligible to receive the vaccine. The education intervention and subsequent option to get the vaccine will be done while the patient is admitted to inpatient care, prior to discharge. The main questions the study aims to answer are: - Will supplemental education about the Prevnar 20 Pneumococcal vaccine influence patient acceptance rates when given a decision to receive it? - Is there any other statistically relevant qualitative reasoning behind the patient's final decision for accepting or refusing the vaccine?

NCT ID: NCT04969614 Not yet recruiting - Clinical trials for Kidney Transplantation

Safety and Immunogenicity of 2-dose Inactivated COVID-19 Vaccine in Kidney Transplant Recipients

Start date: August 1, 2021
Phase:
Study type: Observational

The severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has a major impact on transplant recipients, with mortality rates up to 20%. However, immunocompromised individuals have been excluded from studies of SARS-CoV-2 vaccines. In such patients, the immune response to vaccination may be blunted. To better understand the immunogenicity of SARS-CoV-2 vaccines in transplant recipients, we quantified the humoral response to SARS-CoV-2 vaccine in kidney transplant recipients.

NCT ID: NCT04573205 Not yet recruiting - Vaccine Clinical Trials

Primary TBE Vaccination for the Elderly

Start date: January 2024
Phase: Phase 4
Study type: Interventional

Tick-borne Encephalitis (TBE) can be prevented by vaccine. Vaccine failure, defined as a case of TBE regardless of previous vaccination, has been described and seems to be more predominant with increasing age, suggesting a less effective immune response following with increasing age. In fact previous studies has shown a reduced antibody response in elderly individuals compared to younger when vaccinated against TBE. As a result, in Sweden, an extra vaccine dose has been recommended during the primary vaccine schedule to individuals > 50 years of age. This alternative vaccine schedule has not been tested. The investigator aim to test if an extra vaccine dose in the primary vaccine schedule for those > 50 years of age improves the immune response and offers a corresponding immunity to younger individuals following TBE vaccination.